Canada - English
Canada - Français
New data clarifies the benefit of chemotherapy in early-stage, node-positive breast cancer patients with Recurrence Score® results of 0 to 25.
For a refined risk estimateof local recurrence
The Oncotype DX GPS assay now fully covered by Medicare for all localized prostate cancer.
Nuclear-specific vs. nuclear-agnostic AR-V7 testing
Help Stage II colon cancer patients understand the power of genomics
Your Oncotype DX score can help you decide.
Oncotype DX has helped thousands of women find out.
When Dan's Colon Recurrence Score came back low, he decided against chemotherapy.
View Drs. Rick Baehner and Josh Routh's webinar reviewing the Oncotype MAP™ Pan-Cancer Tissue Test: Validation and Clinical Utility in Solid Tumors from a Pathologist's Perspective.
Book a meeting with your local rep or request more information on the Oncotype MAP test
Have questions? We're here to help.